Share Name Share Symbol Market Type Share ISIN Share Description
4D Pharma LSE:DDDD London Ordinary Share GB00BJL5BR07 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +6.00p +4.26% 146.75p 143.00p 150.50p 145.00p 144.50p 144.50p 5,253 16:35:20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -24.0 -31.4 - 96.11

4D Pharma Share Discussion Threads

Showing 176 to 198 of 200 messages
Chat Pages: 8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
24/9/2018
08:34
24 September 2018 4D pharma plc (the "Company" or "4D") Thetanix - clinical update and publication of studies 4D announces positive data from Phase Ib study of Thetanix in paediatric Crohn's disease patients and publication of studies showing strong efficacy of Thetanix in preclinical models of IBD 24 September 2018 - 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, today announces positive top-line results for its Phase Ib study of Thetanix in paediatric patients with Crohn's disease. The study achieved its primary objective, demonstrating that Thetanix was well tolerated with a good safety profile. The randomised, double-blind, placebo-controlled study was conducted in two parts, with a single-dose phase and a multiple-dose phase and treated a total of 18 subjects aged 16-18 with Crohn's disease. In the single-dose phase, eight subjects were given a single dose of either Thetanix or placebo. In the multiple-dose phase, 10 subjects were given either Thetanix or placebo twice daily for seven consecutive days. The Company also announces the publication of data demonstrating the efficacy of Thetanix in pre-clinical models of inflammatory bowel disease (IBD). The data, published in the journal Inflammatory Bowel Diseases, showed that Thetanix demonstrated strong efficacy on the primary readouts in two different preclinical models with relevance to Crohn's disease, protecting against weight loss, preventing histopathological changes in the colon and attenuating inflammatory mediators. Using an in vitro co-culture assay, a pirin-like protein (PLP), produced by Thetanix, was also identified as a candidate effector molecule. Recombinant PLP was shown to be protective against colitis in a preclinical model and, like Thetanix, to act on NF-B signalling in vitro. Dr. Alex Stevenson, 4D's Chief Scientific Officer, commented: "These promising results add to the growing body of evidence on the efficacy of Thetanix, further reinforcing its potential as a novel treatment for Crohn's disease. Achieving the primary objective of the Phase Ib study, demonstrating the safety and tolerability of Thetanix, is an important milestone in the development of this programme." The journal article can be found here: https://academic.oup.com/ibdjournal/advance-article-abstract/doi/10.1093/ibd/izy281/5095645
someuwin
30/8/2018
14:05
£5k worth max online buy quote.
someuwin
15/8/2018
11:23
You can still buy below £2. But not for much longer I suspect.
someuwin
14/8/2018
10:18
hxxp://crweworld.com/article/news-provided-by-globenewswire/771431/paper-in-scientific-reports-highlights-ability-of-4d-pharmas-mrx0004-to-protect-against-airway-inflammation-in-severe-asthma
danieldanj
14/8/2018
08:06
Excellent news. 4D looking increasingly undervalued.
someuwin
14/8/2018
07:11
14 August 2018 4D pharma plc (the "Company" or "4D") Publication of data in connection with MRx0004 4D announces publication of data highlighting ability of MRx0004 to protect against airway inflammation in severe asthma Data suggests that MRx0004 is a promising next-generation therapeutic for management of asthma 14 August 2018 - 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, today announces the publication of a paper demonstrating that MRx0004, a live biotherapeutic derived from the human gut microbiome, can protect against airway inflammation by reducing both neutrophilic and eosinophilic infiltration in a mouse model of severe asthma. The paper "Bifidobacterium breve MRx0004 protects against airway inflammation in a severe asthma model by suppressing both neutrophil and eosinophil lung infiltration" (Raftis et al.) is published in the Nature Publishing Group journal Scientific Reports. Asthma is a phenotypically heterogeneous disease. Between 5 and 10 % of asthma patients have a severe form of the disease which is refractory to steroid treatment and whose symptoms cannot be controlled despite the application of high-intensity treatments. In severe asthma, airway inflammation can be predominantly eosinophilic, neutrophilic, or mixed and patients presenting with neutrophilic inflammation have particularly poor treatment options. Severe asthma is estimated to account for more than 60 % of asthma-associated healthcare costs. MRx0004 is a strain of Bifidobacterium breve isolated from the gut microbiome of a healthy human. It was tested prophylactically and therapeutically in a house dust mite mouse model of severe asthma. A strong reduction of neutrophil and eosinophil infiltration was observed in lung bronchoalveolar lavage fluid (BALF) following MRx0004 treatment. Furthermore, MRx0004 had a striking effect on lung histopathology, with a strong reduction of both peribronchiolar and perivascular inflammatory infiltrate. The efficacy of MRx0004 exceeded that of the anti-IL-17 positive control used in the experiment. Dr. Alex Stevenson, 4D's Chief Scientific Officer, commented: "This data provides further evidence that live biotherapeutics have the potential to change the way we treat disease. Using MRx0004, we have demonstrated superior efficacy to biologics in a severe and steroid-resistant model of asthma." He added: "Perhaps more significantly, we have shown that MRx0004 can strongly reduce neutrophil and eosinophil airway infiltration concurrently. This is something which is not achievable with current therapies and is further evidence of the potential of MRx0004 as a next-generation therapeutic for the management of asthma." Please find a copy of the paper here: http://www.nature.com/articles/s41598-018-30448-z
someuwin
31/7/2018
12:57
4d Pharma could be a £1bn company in the next few years or is that just blue sky thinking?
jamjason
31/7/2018
12:13
Good to see DDDD responding to the buying. Re; buying. It's simply there are many more buy orders in the queue than sellers of the shares. The bid/ask totals are 31k v only 8k.....165.5p v 175p. That 8k comprises the sum total of what's being offered via 4 mm's....2k shrs from each - so no wonder the full ask is having to be paid. Hope this useful as any holding back on buying is likely to see higher, from how I read the position. gla, f
fillipe
31/7/2018
10:16
Can buy £5k online. But not £6k.
someuwin
30/7/2018
15:57
Yes - could get another big move up soon.
someuwin
30/7/2018
15:51
It appears the market is liking today's two RNS's. f
fillipe
30/7/2018
10:26
4D Pharma (DDDD) News Out Just Now http://crweworld.com/article/news-provided-by-globenewswire/753164/4d-announces-publication-of-data-showing-potential-of-single-bacterial-strains-from-the-human-gut-microbiota-to-serve-as-novel-hdac-inhibitors
danieldanj
27/7/2018
14:24
fillipe, why do you think now is a good time to buy?
jamjason
27/7/2018
14:22
James Henderson said the share price should never have gone as high as it did. Talk about kicking yourself in the foot!
jamjason
27/7/2018
10:00
It's time to take a few here, I'm feeling. Can be got for just under 154p. f
fillipe
26/7/2018
18:50
Article in Today's Shares Magazine. James Henderson from Lowland Investment Company... "...He also likes drug company 4D Pharma (DDDD:AIM) which he calls a well-funded company with drugs being tested and which has an attractive tie-up with pharma giant Merck. 'Sometimes stocks get overhyped and people get bored of them so the share price drifts. That's happened with 4D Pharma yet real progress is being made with its portfolio."
someuwin
26/7/2018
16:18
Huge sells going through today
jamjason
24/7/2018
18:14
You too mate, I hope both companies take off in the near future
jamjason
24/7/2018
17:51
Good luck jamjason
onedayrodders
24/7/2018
12:13
onedayrodders, I understand where you're coming from but I'm happy to back 4D Pharma over Opti even if I think there will be further placings this year to fund the next phase of trials. I'm not sure how much cash is left in the bank but I think it's around £30m, which is not very much to fund development for the next few years and pay for the in-house manufacturing provided the IBS or Crohns drug find route to market.
jamjason
24/7/2018
08:30
Hi jamjason ... Optibiotix is booming for precisely THAT reason ... ie it's deliberately not going down the Pharma route that needs £500m-£1b and 5-10 years of FDA trials and tribulations with no guarantees, before products and revenues. OPTI have the science proven already, Winning top industry awards, products selling and repeat orders, and have $100b companies paying them for the privilege of working on adding their science to their products. Just one of their products is a fibre that replaces sugar 100%, tastes sweeter, can be added to any food and drink, with zero bitter after taste like those awful sweeteners...And has ZERO calories ,,, this is the holy grail and explains why a $100b company has paid OPTI for an exclusive period. This fibre has been independently taste tested already. So no offence but it's wrong to compare DDDD with OPTI, same science but 2 totally different strategies.
onedayrodders
23/7/2018
19:57
Optibiotix is booming and it's not even a pharma in the microbiome field. 4d Pharma's turn next....
jamjason
21/7/2018
18:35
Can nobody confirm how much cash 4d Pharma has left in the bank???
jamjason
Chat Pages: 8  7  6  5  4  3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20181015 19:14:13